Aspiro Therapeutics Joins Biotechnology Innovation Organization (BIO)
Tucson, AZ / Jan. 22, 2025–Aspiro Therapeutics, a pioneering biotech company dedicated to developing advanced treatments for obstructive lung diseases, is excited to announce its membership with the Biotechnology Innovation Organization (BIO.org). By joining the world’s largest trade association representing the biotechnology industry, Aspiro reaffirms its commitment to advancing groundbreaking science and fostering collaboration across […]
Aspiro Therapeutics and University of Arizona Awarded Follow-On Funding from the Flinn Foundation
Tucson, AZ / January 13, 2025 – Aspiro Therapeutics, in collaboration with the University of Arizona, is honored to announce it has been awarded follow-on funding through the Flinn Foundation Seed Grants to Promote Translational Research program. This additional $100,000 funding underscores the team’s continued progress in developing innovative therapies for obstructive lung diseases. The follow-on […]
Aspiro Therapeutics to Present at Biotech Showcase™ 2025
Pioneering a Novel Disease-Modifying Therapy for Obstructive Lung Disease San Francisco, CA / Jan. 8 2025—Aspiro Therapeutics, an innovator developing an advanced, disease-modifying therapy that targets obstructive lung diseases, today announced that its CEO, James Lovgren, will present at Seed Showcase™, part of Biotech Showcase 2025. The presentation, “A Novel Therapy to Treat Obstructive […]
Aspiro Therapeutics Acknowledges Co-Founder Dr. Julie Ledford’s Flinn Foundation Seed Grant for Pioneering Research in Respiratory Health
Tucson, AZ / May 1, 2024 – Aspiro Therapeutics proudly highlights the foundational work of co-founder Dr. Julie Ledford, whose research, funded by a Flinn Foundation Seed Grant awarded in June 2023, played a key role in Aspiro’s formation and scientific direction. Awarded through her role at the University of Arizona, Dr. Ledford’s research focuses on […]